JP6849896B2 - 上皮バリア機能増強特性を有するアジスロマイシン誘導体 - Google Patents

上皮バリア機能増強特性を有するアジスロマイシン誘導体 Download PDF

Info

Publication number
JP6849896B2
JP6849896B2 JP2018526129A JP2018526129A JP6849896B2 JP 6849896 B2 JP6849896 B2 JP 6849896B2 JP 2018526129 A JP2018526129 A JP 2018526129A JP 2018526129 A JP2018526129 A JP 2018526129A JP 6849896 B2 JP6849896 B2 JP 6849896B2
Authority
JP
Japan
Prior art keywords
alkyl
aryl
group
tetrahydropyran
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018526129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018534324A5 (https=
JP2018534324A (ja
Inventor
ルナー ガーダルソン，フリドリック
ルナー ガーダルソン，フリドリック
レーマン，フレドリック
テオドロビック，ペーター
Original Assignee
エピエンド ファーマシューティカルズ イーエッチエフ．
エピエンド ファーマシューティカルズ イーエッチエフ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55133040&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6849896(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エピエンド ファーマシューティカルズ イーエッチエフ．, エピエンド ファーマシューティカルズ イーエッチエフ． filed Critical エピエンド ファーマシューティカルズ イーエッチエフ．
Publication of JP2018534324A publication Critical patent/JP2018534324A/ja
Publication of JP2018534324A5 publication Critical patent/JP2018534324A5/ja
Application granted granted Critical
Publication of JP6849896B2 publication Critical patent/JP6849896B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Materials For Medical Uses (AREA)
JP2018526129A 2015-11-19 2016-11-21 上皮バリア機能増強特性を有するアジスロマイシン誘導体 Active JP6849896B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1520419.1 2015-11-19
GBGB1520419.1A GB201520419D0 (en) 2015-11-19 2015-11-19 Compounds
PCT/EP2016/078360 WO2017085329A1 (en) 2015-11-19 2016-11-21 Azithromycin derivatives with epithelial barrier enhancement properties

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021019109A Division JP7256558B2 (ja) 2015-11-19 2021-02-09 上皮バリア機能増強特性を有するアジスロマイシン誘導体

Publications (3)

Publication Number Publication Date
JP2018534324A JP2018534324A (ja) 2018-11-22
JP2018534324A5 JP2018534324A5 (https=) 2021-01-28
JP6849896B2 true JP6849896B2 (ja) 2021-03-31

Family

ID=55133040

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018526129A Active JP6849896B2 (ja) 2015-11-19 2016-11-21 上皮バリア機能増強特性を有するアジスロマイシン誘導体
JP2021019109A Active JP7256558B2 (ja) 2015-11-19 2021-02-09 上皮バリア機能増強特性を有するアジスロマイシン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021019109A Active JP7256558B2 (ja) 2015-11-19 2021-02-09 上皮バリア機能増強特性を有するアジスロマイシン誘導体

Country Status (19)

Country Link
US (3) US10723752B2 (https=)
EP (2) EP3377511B1 (https=)
JP (2) JP6849896B2 (https=)
KR (2) KR20240157138A (https=)
CN (2) CN108290919B (https=)
CA (1) CA3005088A1 (https=)
CY (1) CY1123418T1 (https=)
DK (1) DK3377511T3 (https=)
ES (1) ES2810703T3 (https=)
GB (1) GB201520419D0 (https=)
HR (1) HRP20201246T1 (https=)
HU (1) HUE050307T2 (https=)
LT (1) LT3377511T (https=)
PL (1) PL3377511T3 (https=)
PT (1) PT3377511T (https=)
RS (1) RS60698B1 (https=)
SI (1) SI3377511T1 (https=)
SM (1) SMT202000426T1 (https=)
WO (1) WO2017085329A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021073303A (ja) * 2015-11-19 2021-05-13 エピエンド ファーマシューティカルズ イーエッチエフ． 上皮バリア機能増強特性を有するアジスロマイシン誘導体

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220156570A (ko) 2020-03-12 2022-11-25 조에티스 서비시즈 엘엘씨 면역조절성 유레아 아잘라이드
AU2022343476B2 (en) * 2021-09-07 2025-02-20 Zoetis Services Llc Immunomodulating azalides
CN121038797A (zh) 2023-03-22 2025-11-28 艾比恩多制药有限责任公司 用于治疗嗜酸性粒细胞相关疾病的阿奇霉素衍生物
GB202404587D0 (en) 2024-03-28 2024-05-15 Epiendo Pharmaceuticals Ehf Chemical forms
GB202412461D0 (en) 2024-08-23 2024-10-09 Epiendo Pharmaceuticals Ehf Medial use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725385A (en) 1970-11-02 1973-04-03 Abbott Lab Process for the demethylation of 3-amino macrolides
HRP20010018A2 (en) * 2001-01-09 2002-12-31 Pliva D D Novel anti-inflammatory compounds
AU2003219770B2 (en) * 2002-02-15 2008-10-09 Merckle Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
RU2330858C2 (ru) 2002-07-08 2008-08-10 Глаксомитклайн Истраживацки Центар Загреб Д.О.О. Новые соединения, составы и способы лечения воспалительных заболеваний и состояний
ITMI20022292A1 (it) 2002-10-29 2004-04-30 Zambon Spa 9a-azalidi ad attivita' antiinfiammatoria.
GB0310984D0 (en) * 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
US7767797B1 (en) * 2004-09-30 2010-08-03 Synovo Gmbh Macrocyclic compounds and methods of use thereof
PT1851236E (pt) 2005-01-13 2010-10-25 Glaxosmithkline Zagreb Macrólidos com actividade anti-inflamatória
EP1841776B1 (en) * 2005-01-13 2008-12-31 GlaxoSmithKline istrazivacki centar Zagreb d.o.o. Decladinosyl-macrolides with anti-inflammatory activity
CN1837225A (zh) 2005-08-23 2006-09-27 济南思创生物技术有限公司 阿奇霉素衍生物及其制法和药物应用
RU2455308C2 (ru) 2006-05-01 2012-07-10 Тайсо Фармасьютикал Ко., Лтд. Макролидные производные
CN101074251B (zh) * 2007-06-22 2011-06-15 山东大学 阿奇霉素4＂-氨甲酸酯衍生物、制备方法及其药物组合物
WO2009006403A2 (en) * 2007-06-29 2009-01-08 Georgia Tech Research Corporation Non-peptide macrocyclic histone deacetylase (hdac) inhibitors and methods of making and using thereof
WO2010086351A1 (en) * 2009-01-30 2010-08-05 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. 3'-n-substituted 9-deoxo-9a-methyl-9a-aza-homoerythromycin having antimalarial activity
CA2814333A1 (en) * 2010-10-10 2012-04-19 Synovo Gmbh Anti-inflammatory macrolides
GB201105633D0 (en) * 2011-04-01 2011-05-18 Norbrook Lab Ltd Antibotic compounds
EP2831083A4 (en) * 2012-03-27 2016-03-09 Michael W Burnet INFLAMMATORY MAKROLIDE
AU2014252462A1 (en) 2013-04-10 2015-10-01 Probiotic Pharmaceuticals Aps Azithromycin antimicrobial derivatives with non-antibiotic pharmaceutical effect
GB201520419D0 (en) 2015-11-19 2016-01-06 Epi Endo Pharmaceuticals Ehf Compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021073303A (ja) * 2015-11-19 2021-05-13 エピエンド ファーマシューティカルズ イーエッチエフ． 上皮バリア機能増強特性を有するアジスロマイシン誘導体
JP7256558B2 (ja) 2015-11-19 2023-04-12 エピエンド ファーマシューティカルズ イーエッチエフ． 上皮バリア機能増強特性を有するアジスロマイシン誘導体

Also Published As

Publication number Publication date
HRP20201246T1 (hr) 2020-11-13
US20220106349A1 (en) 2022-04-07
WO2017085329A1 (en) 2017-05-26
HUE050307T2 (hu) 2020-11-30
CN108290919B (zh) 2022-06-17
SI3377511T1 (sl) 2020-10-30
US20200317710A1 (en) 2020-10-08
CN108290919A (zh) 2018-07-17
KR20240157138A (ko) 2024-10-31
PL3377511T3 (pl) 2020-11-16
US12049477B2 (en) 2024-07-30
CY1123418T1 (el) 2021-12-31
CN114933620B (zh) 2026-03-31
EP3708573A1 (en) 2020-09-16
JP2018534324A (ja) 2018-11-22
US20180354981A1 (en) 2018-12-13
LT3377511T (lt) 2020-09-25
US10723752B2 (en) 2020-07-28
EP3377511A1 (en) 2018-09-26
RS60698B1 (sr) 2020-09-30
JP2021073303A (ja) 2021-05-13
KR102724114B1 (ko) 2024-10-29
HK1255270A1 (en) 2019-08-09
JP7256558B2 (ja) 2023-04-12
US11236120B2 (en) 2022-02-01
DK3377511T3 (da) 2020-08-17
ES2810703T3 (es) 2021-03-09
CA3005088A1 (en) 2017-05-26
PT3377511T (pt) 2020-08-21
EP3377511B1 (en) 2020-05-13
GB201520419D0 (en) 2016-01-06
CN114933620A (zh) 2022-08-23
KR20180077282A (ko) 2018-07-06
SMT202000426T1 (it) 2020-09-10

Similar Documents

Publication Publication Date Title
JP7256558B2 (ja) 上皮バリア機能増強特性を有するアジスロマイシン誘導体
CN109641873B (zh) N-(吡啶-2-基)吡啶-磺酰胺衍生物及其用于疾病治疗的用途
JP5805389B2 (ja) 非経口用抗菌剤
TW201529578A (zh) 抗病毒治療用的吡唑並［１，５-ａ］嘧啶類
CN105228605A (zh) 硫代糖粘液溶解剂
CN116496318A (zh) 一种杂环衍生物及其组合物和药学上的应用
TW201038277A (en) Anti-inflammatory macrolide
CN101117336A (zh) 7-(4-肟基-3-氨基-1-哌啶基)喹啉羧酸衍生物及其制备方法
JP2026512285A (ja) 好酸球関連疾患の治療における使用のためのアジスロマイシン誘導体
HK40037271A (en) Azithromycin derivatives with epithelial barrier enhancement properties
HK1255270B (en) Azithromycin derivatives with epithelial barrier enhancement properties
CN106103423A (zh) 化学化合物
PT1664056E (pt) Poliéteres pentacíclicos fundidos
CN101450947B (zh) 7-(3-肟基-4-氨基-4-烷基-1-哌啶基)喹啉羧酸衍生物及其制备方法
WO2021138847A1 (en) Macrolide compound and its use of treatment chronic respiratory disease
HK1230601A1 (en) Pyrazine compounds
HK1181047B (en) Alkaloid aminoester derivatives and medicinal composition thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201204

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20201204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210209

R150 Certificate of patent or registration of utility model

Ref document number: 6849896

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250